<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Qiagen NV</title>
	<atom:link href="http://www.stockbloghub.com/tag/qiagen-nv/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(QGEN) Qiagen Beats Earnings Forecasts &#8211; Reiterates Outllook</title>
		<link>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817</link>
		<comments>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99817</guid>
		<description><![CDATA[Qiagen’s (QGEN) first quarter 2012 earnings of 12 cents per share remained flat on a year-over-year basis. However, adjusting for certain one-time items, EPS came in at 23 cents in the first quarter, beating the Zacks Consensus Estimate of 19 cents as well as the year-ago quarter earnings by a couple of cents. The improvement in the bottom line was driven by double–digit sales growth and efficient cost management. In the fourth quarter, all the operational regions of the company delivered double-digit growth at CER. Region wise, Americas (47% of revenues) witnessed a 15% increase in sales at CER, driven by strong contributions from the US, Brazil and Canada. However, revenues from Europe- Middle East-Africa (34% of sales) and Asia-Pacific /Japan (18% of sales) increased 12% and 18% at CER, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/qgen-qiagen-beats-earnings-forecasts-reiterates-outllook/99817/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Added in Russell 1000 and 3000</title>
		<link>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895</link>
		<comments>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:57:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77895</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) announced that it has been included in the Russell 1000 and the Russell 3000 Indices. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe and includes approximately 1,000 of the largest securities based on a combination of their market cap and current index. On the other hand, the Russell 3000 index evaluates the performance of the 3,000 largest U.S. companies by market capitalization. The constituents of the indices will remain in place for a year. Qiagen is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.  Over the years, the company  has developed a comprehensive portfolio of more than 500 proprietary, consumable products, and automated solutions for sample collection.  The company specializes in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/qgen-qiagen-added-in-russell-1000-and-3000/77895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Ties Up with Pharma Majors</title>
		<link>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570</link>
		<comments>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Natural Gas Services Group Inc]]></category>
		<category><![CDATA[Neuberger Berman High Yield Strategies Fund]]></category>
		<category><![CDATA[NGS]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77570</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently strengthened its newly created Technology Strategy Board grant consortium with the inclusion of the R&#38;D divisions of AstraZeneca (AZN) and Johnson &#38; Johnson (JNJ). The group expects this grant to fund the development of a commercial multi-gene next generation sequencing test, which will provide comprehensive molecular profiles of tumors and identify treatment options. Life Technologies believes that the test will increase the speed and accuracy of cancer treatment. With the application of the next generation sequencing (NGS) and informatics, this genomic test will be commercially available in the global market. This program will attract additional pharmaceutical clinical trial investments in UK that should prove to be a major source of international investment. Thus, the consortium expects this new program to add life to the economic condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/life-life-technologies-ties-up-with-pharma-majors/77570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Hopeful of Ipsogen Takeover</title>
		<link>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626</link>
		<comments>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626#comments</comments>
		<pubDate>Mon, 20 Jun 2011 00:33:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76626</guid>
		<description><![CDATA[Recently, Qiagen (QGEN) entered into an agreement to acquire 47% stake in France based Ipsogen at €12.90 per share. Thereafter, Qiagen wishes to make a public offer to fully acquire the company. With Ipsogen, Qiagen would have access to a wide portfolio of biomarkers targeted to patients suffering from with blood cancer. Ipsogen recorded 24% sales growth in 2010 to €8.4 million (approximately $11 million). The total value on fully acquiring Ipsogen would stand at €70 million (fully diluted) or $101 million (at exchange rate of €1.00 = $1.44). The whole transaction (including the public offer) is expected to be completed by the third quarter of 2011. Qiagen would fund this acquisition using its existing cash balance. The transaction, on an adjusted basis, would be slightly dilutive to adjusted EPS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/qgen-qiagen-hopeful-of-ipsogen-takeover/76626/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LIFE) Life Technologies Deals with Luminex</title>
		<link>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397</link>
		<comments>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397#comments</comments>
		<pubDate>Tue, 14 Jun 2011 18:56:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75397</guid>
		<description><![CDATA[Life Technologies Corporation (LIFE) recently entered into a global sales and distribution agreement with Luminex Corporation (LMNX) to access the latter’s award-winning multiplexing instrument MAGPIX to analyze proteins for research. This partnership is expected to be beneficial for MAGPIX as Life caters to scientists and researchers worldwide. On the other hand, Life expects MAGPIX to expand its cutting-edge antibody content across a broad range of protein quantitation needed in basic and clinical research. MAGPIX (launched in July 2010) is a compact, multiplex analyzer that helps efficient detection of 50 different analytes on a single sample, including proteins and nucleic acids. This product received the Medical Design Excellence Award in 2011 for its innovative design and contribution and recently received CE IVD mark in Europe. Life earns revenues from three divisions ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/life-life-technologies-deals-with-luminex/75397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Earnings Report Shows Strong Growth</title>
		<link>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177</link>
		<comments>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177#comments</comments>
		<pubDate>Wed, 04 May 2011 16:37:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73177</guid>
		<description><![CDATA[Hologic (HOLX) reported an adjusted EPS of 30 cents during the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues were $438.7 million, an increase of 4.9% compared to the prior-year quarter and higher than the Zacks Consensus Estimate of $433 million. Hologic operates through four segments ? Breast Health, Diagnostics, GYN (Gynecology) Surgical and Skeletal Health ? which contributed 47%, 32%, 16% and 5%, respectively to the total revenue during the quarter. Barring Diagnostics revenue, which declined 1.2% to $138.2 million during the quarter, the other three segments recorded a robust growth of 8.7% ($205.9 million), 6.5% ($71.5 million) and 7.1% ($23.1 million), respectively. The strong growth witnessed by Breast Health was primarily driven by the rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

